
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is a promising clinical-stage biopharmaceutical company with a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for the treatment of cancer and other immune-mediated diseases. With a unique platform using iNKT cells and their therapeutic advantages, such as tissue homing and tumor clearance, MiNK Therapeutics has the potential for long-term success in the biopharmaceutical industry. While the company will likely need additional financing in the next two decades and faces delisting risk if share values drop, its focus on intellectual property protection adds another layer of stability and growth potential.
Bears say
MiNK Therapeutics is facing potential challenges in achieving its projected $35 price target as a result of factors such as safety concerns with clinical or preclinical programs, lower-than-expected efficacy, potential competition in the market, and regulatory obstacles. Our Buy rating and price target are contingent on the success of its single product candidate, agenT-797, for which we only assign value for two indications and have not factored in other pipeline assets in our valuation. (Words Count: 117)
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares